How much did La Jolla Pharmaceutical achieve in EBIT for the current year?
In the current year, La Jolla Pharmaceutical has achieved an EBIT of 18.25 M USD.
In 2024, La Jolla Pharmaceutical's EBIT was 18.25 M USD, a 104.38% increase from the 8.93 M USD EBIT recorded in the previous year.
YEAR | EBIT (undefined USD) |
---|---|
2026e | 77.6 |
2025e | 44.5 |
2024e | 18.25 |
2023e | 8.93 |
2022e | 2.28 |
2021 | 21.83 |
2020 | -35.84 |
2019 | -109.8 |
2018 | -194.05 |
2017 | -115.43 |
2016 | -78.37 |
2015 | -41.97 |
2014 | -21.34 |
2013 | -17.94 |
2012 | -10.74 |
2011 | -2.27 |
2010 | -3.93 |
2009 | -8.64 |
2008 | -60.73 |
2007 | -55.69 |
2006 | -42.13 |
2005 | -28 |
2004 | -40.74 |
2003 | -39.29 |
2002 | -44.64 |
3 years
5 years
10 years
25 Years
Max
Gain insights into La Jolla Pharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by La Jolla Pharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects La Jolla Pharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of La Jolla Pharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into La Jolla Pharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing La Jolla Pharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on La Jolla Pharmaceutical’s growth potential.
Date | La Jolla Pharmaceutical Revenue | La Jolla Pharmaceutical EBIT | La Jolla Pharmaceutical Net Income |
---|---|---|---|
2026e | 93.75 M undefined | 77.6 M undefined | 75.07 M undefined |
2025e | 87.23 M undefined | 44.5 M undefined | 30.03 M undefined |
2024e | 77.41 M undefined | 18.25 M undefined | 12.25 M undefined |
2023e | 65.23 M undefined | 8.93 M undefined | 6 M undefined |
2022e | 53.84 M undefined | 2.28 M undefined | 1.04 M undefined |
2021 | 75.72 M undefined | 21.83 M undefined | 19.66 M undefined |
2020 | 33.42 M undefined | -35.84 M undefined | -39.42 M undefined |
2019 | 23.05 M undefined | -109.8 M undefined | -116.51 M undefined |
2018 | 10.06 M undefined | -194.05 M undefined | -199.47 M undefined |
2017 | 0 undefined | -115.43 M undefined | -114.8 M undefined |
2016 | 620,000 undefined | -78.37 M undefined | -78.19 M undefined |
2015 | 1.06 M undefined | -41.97 M undefined | -41.91 M undefined |
2014 | 0 undefined | -21.34 M undefined | -21.31 M undefined |
2013 | 0 undefined | -17.94 M undefined | -18.74 M undefined |
2012 | 0 undefined | -10.74 M undefined | -8.52 M undefined |
2011 | 0 undefined | -2.27 M undefined | -11.67 M undefined |
2010 | 0 undefined | -3.93 M undefined | -4.23 M undefined |
2009 | 8.13 M undefined | -8.64 M undefined | -8.63 M undefined |
2008 | 0 undefined | -60.73 M undefined | -62.85 M undefined |
2007 | 0 undefined | -55.69 M undefined | -53.08 M undefined |
2006 | 0 undefined | -42.13 M undefined | -39.45 M undefined |
2005 | 0 undefined | -28 M undefined | -27.36 M undefined |
2004 | 0 undefined | -40.74 M undefined | -40.54 M undefined |
2003 | 0 undefined | -39.29 M undefined | -38.84 M undefined |
2002 | 0 undefined | -44.64 M undefined | -43.32 M undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2002 | 0 USD | -44.64 M USD | -43.32 M USD |
2003 | 0 USD | -39.29 M USD | -38.84 M USD |
2004 | 0 USD | -40.74 M USD | -40.54 M USD |
2005 | 0 USD | -28 M USD | -27.36 M USD |
2006 | 0 USD | -42.13 M USD | -39.45 M USD |
2007 | 0 USD | -55.69 M USD | -53.08 M USD |
2008 | 0 USD | -60.73 M USD | -62.85 M USD |
2009 | 8.13 M USD | -8.64 M USD | -8.63 M USD |
2010 | 0 USD | -3.93 M USD | -4.23 M USD |
2011 | 0 USD | -2.27 M USD | -11.67 M USD |
2012 | 0 USD | -10.74 M USD | -8.52 M USD |
2013 | 0 USD | -17.94 M USD | -18.74 M USD |
2014 | 0 USD | -21.34 M USD | -21.31 M USD |
2015 | 1.06 M USD | -41.97 M USD | -41.91 M USD |
2016 | 620,000 USD | -78.37 M USD | -78.19 M USD |
2017 | 0 USD | -115.43 M USD | -114.8 M USD |
2018 | 10.06 M USD | -194.05 M USD | -199.47 M USD |
2019 | 23.05 M USD | -109.8 M USD | -116.51 M USD |
2020 | 33.42 M USD | -35.84 M USD | -39.42 M USD |
2021 | 75.72 M USD | 21.83 M USD | 19.66 M USD |
2022e | 53.84 M USD | 2.28 M USD | 1.04 M USD |
2023e | 65.23 M USD | 8.93 M USD | 6 M USD |
2024e | 77.41 M USD | 18.25 M USD | 12.25 M USD |
2025e | 87.23 M USD | 44.5 M USD | 30.03 M USD |
2026e | 93.75 M USD | 77.6 M USD | 75.07 M USD |
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the La Jolla Pharmaceutical's sales revenue. A higher gross margin percentage indicates that the La Jolla Pharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the La Jolla Pharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the La Jolla Pharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the La Jolla Pharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the La Jolla Pharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the La Jolla Pharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
La Jolla Pharmaceutical Gross margin | La Jolla Pharmaceutical Profit margin | La Jolla Pharmaceutical EBIT margin | La Jolla Pharmaceutical Profit margin |
---|---|---|---|
2026e | 82.19 % | 82.78 % | 80.08 % |
2025e | 82.19 % | 51.01 % | 34.42 % |
2024e | 82.19 % | 23.57 % | 15.83 % |
2023e | 82.19 % | 13.69 % | 9.19 % |
2022e | 82.19 % | 4.23 % | 1.94 % |
2021 | 82.19 % | 28.83 % | 25.96 % |
2020 | 76.6 % | -107.24 % | -117.95 % |
2019 | 89.63 % | -476.36 % | -505.47 % |
2018 | 83.6 % | -1,928.93 % | -1,982.8 % |
2017 | 82.19 % | 0 % | 0 % |
2016 | 82.19 % | -12,640.32 % | -12,611.29 % |
2015 | 82.19 % | -3,959.43 % | -3,953.77 % |
2014 | 82.19 % | 0 % | 0 % |
2013 | 82.19 % | 0 % | 0 % |
2012 | 82.19 % | 0 % | 0 % |
2011 | 82.19 % | 0 % | 0 % |
2010 | 82.19 % | 0 % | 0 % |
2009 | 82.19 % | -106.27 % | -106.15 % |
2008 | 82.19 % | 0 % | 0 % |
2007 | 82.19 % | 0 % | 0 % |
2006 | 82.19 % | 0 % | 0 % |
2005 | 82.19 % | 0 % | 0 % |
2004 | 82.19 % | 0 % | 0 % |
2003 | 82.19 % | 0 % | 0 % |
2002 | 82.19 % | 0 % | 0 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2002 | 82.19 % | 0 % | 0 % |
2003 | 82.19 % | 0 % | 0 % |
2004 | 82.19 % | 0 % | 0 % |
2005 | 82.19 % | 0 % | 0 % |
2006 | 82.19 % | 0 % | 0 % |
2007 | 82.19 % | 0 % | 0 % |
2008 | 82.19 % | 0 % | 0 % |
2009 | 82.19 % | -106.27 % | -106.15 % |
2010 | 82.19 % | 0 % | 0 % |
2011 | 82.19 % | 0 % | 0 % |
2012 | 82.19 % | 0 % | 0 % |
2013 | 82.19 % | 0 % | 0 % |
2014 | 82.19 % | 0 % | 0 % |
2015 | 82.19 % | -3,959.43 % | -3,953.77 % |
2016 | 82.19 % | -12,640.32 % | -12,611.29 % |
2017 | 82.19 % | 0 % | 0 % |
2018 | 83.6 % | -1,928.93 % | -1,982.8 % |
2019 | 89.63 % | -476.36 % | -505.47 % |
2020 | 76.6 % | -107.24 % | -117.95 % |
2021 | 82.19 % | 28.83 % | 25.96 % |
2022e | 82.19 % | 4.23 % | 1.94 % |
2023e | 82.19 % | 13.69 % | 9.19 % |
2024e | 82.19 % | 23.57 % | 15.83 % |
2025e | 82.19 % | 51.01 % | 34.42 % |
2026e | 82.19 % | 82.78 % | 80.08 % |
La Jolla Pharmaceutical's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
A yearly comparison of La Jolla Pharmaceutical's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
La Jolla Pharmaceutical's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Fluctuations in La Jolla Pharmaceutical’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
In the current year, La Jolla Pharmaceutical has achieved an EBIT of 18.25 M USD.
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company La Jolla Pharmaceutical.
The EBIT of La Jolla Pharmaceutical has increased by 104.379% increased compared to the previous year.
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
The EBIT of La Jolla Pharmaceutical is listed in the income statement.
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
Over the past 12 months, La Jolla Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, La Jolla Pharmaceutical is expected to pay a dividend of 0 USD.
The current dividend yield of La Jolla Pharmaceutical is .
La Jolla Pharmaceutical pays a quarterly dividend. This is distributed in the months of .
La Jolla Pharmaceutical paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
La Jolla Pharmaceutical is assigned to the 'Health' sector.
To receive the latest dividend of La Jolla Pharmaceutical from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
The last dividend was paid out on 9/10/2024.
In the year 2023, La Jolla Pharmaceutical distributed 0 USD as dividends.
The dividends of La Jolla Pharmaceutical are distributed in USD.
The La Jolla Pharmaceutical stock can be added to a savings plan with the following providers: Trade Republic
Our stock analysis for La Jolla Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of La Jolla Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.